Related Experiment Video
Updated: Aug 3, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
Farhan Azad1, Clive J Miranda1, Al Amin2
1Internal Medicine, University at Buffalo, Buffalo, USA.
Abstract:
Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential in this patient population. Complement inhibitors have been used, and our patient improved on eculizumab therapy.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Venous Thrombosis III: Interprofessional Care
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents